If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply
Objective: Include inhaled levodopa as a therapeutic option in those patients who, due to post-surgical problems, cannot use oral treatments. Background: The development of motor…Wearable sensors and AI in Parkinson’s disease – How continuous symptom and treatment response monitoring can enable better clinical decision making – Interim results from an observational study
Objective: To investigate how continuous objective information on motor symptoms and treatment response combined with subjective patient reported insights can be used to optimize Parkinson’s…NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)
Objective: To assess the safety, tolerability and preliminary efficacy of NLX-112 (a.k.a. befiradol) in patients with moderate to severe LID in PD: a randomized, double-blind,…What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…The diagnosis value of dopaminergic responsiveness of Parkinson’s disease： a systematic review and meta-analysis
Objective: aimed to confirm the diagnostic value/accuracy of levodopa and/or apomorphine challenge test in parkinsonian syndromes (PDS) to assess their value in the diagnosis of…Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Effect of levodopa on the interpretation of social interactions in people living with Parkinson’s disease
Objective: Better understand the social interactions by assessing the effect of oral levodopa on the social cognition abilities in fluctuating PD patients without significant cognitive disorder.…Home-based titration with Duodenal infusion of Levodopa in People with Parkinson’s disease: an observational feasibility study
Objective: Primary objectives were to assess the feasibility and safety of LCIG home titration with use of telemedicine-assisted (TM) technology, and patient/caregivers satisfaction. Secondly, to…Increased alpha power in basal ganglia and thalamus following levodopa administration in a dystonic young adult
Objective: To evaluate effects of acute levodopa administration on frequency content of intracranial local field potentials in a dystonic young adult. Background: Levodopa is the…Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 70
- Next Page »